RU95112456A - Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения - Google Patents

Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения

Info

Publication number
RU95112456A
RU95112456A RU95112456/04A RU95112456A RU95112456A RU 95112456 A RU95112456 A RU 95112456A RU 95112456/04 A RU95112456/04 A RU 95112456/04A RU 95112456 A RU95112456 A RU 95112456A RU 95112456 A RU95112456 A RU 95112456A
Authority
RU
Russia
Prior art keywords
derivatives
synthesis
alanine
antagonists
beta
Prior art date
Application number
RU95112456/04A
Other languages
English (en)
Other versions
RU2161155C2 (ru
Inventor
Охкубо Митсуру
Jp]
Такахаси Фумие
Яманака Тосио
Сакаи Хироеси
Като Масаюки
Original Assignee
Фудзисава Фармасьютикал Ко.
Фудзисава Фармасьютикал Ко., Лтд.
Лтд. (Jp)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939319561A external-priority patent/GB9319561D0/en
Priority claimed from GB9413936A external-priority patent/GB9413936D0/en
Application filed by Фудзисава Фармасьютикал Ко., Фудзисава Фармасьютикал Ко., Лтд., Лтд. (Jp) filed Critical Фудзисава Фармасьютикал Ко.
Publication of RU95112456A publication Critical patent/RU95112456A/ru
Application granted granted Critical
Publication of RU2161155C2 publication Critical patent/RU2161155C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Предлагаемое изобретение относится к производным β-аланина, представленным следующей формулойв которой символы имеют значения, указанные в описании изобретения, и фармацевтически пригодным солям этих производных которые являются антагонистом гликопротсина IIb/IIIa, ингибитором агрегирования тромбоцитов и ингибитором связывания фибриногена с тромбоцитами, способам получения их, фармацевтическому препарату, содержащему это соединение, и способу предупреждения и/или лечения указанных в описании изобретения заболеваний человека или животного.

Claims (1)

  1. Предлагаемое изобретение относится к производным β-аланина, представленным следующей формулой
    Figure 00000001

    в которой символы имеют значения, указанные в описании изобретения, и фармацевтически пригодным солям этих производных которые являются антагонистом гликопротсина IIb/IIIa, ингибитором агрегирования тромбоцитов и ингибитором связывания фибриногена с тромбоцитами, способам получения их, фармацевтическому препарату, содержащему это соединение, и способу предупреждения и/или лечения указанных в описании изобретения заболеваний человека или животного.
RU95112456/04A 1993-09-22 1994-09-21 Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения RU2161155C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB939319561A GB9319561D0 (en) 1993-09-22 1993-09-22 Beta-alanine derivative and a process for preparation thereof
GB9319561.8 1993-09-22
GB9413936A GB9413936D0 (en) 1994-07-11 1994-07-11 Beta-Alanine derivative and a process for the preparation thereof
GB9413936.7 1994-07-11
PCT/JP1994/001550 WO1995008536A1 (en) 1993-09-22 1994-09-21 N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists

Publications (2)

Publication Number Publication Date
RU95112456A true RU95112456A (ru) 1997-04-20
RU2161155C2 RU2161155C2 (ru) 2000-12-27

Family

ID=26303555

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95112456/04A RU2161155C2 (ru) 1993-09-22 1994-09-21 Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения

Country Status (16)

Country Link
US (1) US6380215B1 (ru)
EP (2) EP0669912B1 (ru)
CN (1) CN1041919C (ru)
AT (1) ATE210118T1 (ru)
AU (1) AU684547B2 (ru)
CA (1) CA2157792C (ru)
DE (1) DE69429328T2 (ru)
DK (1) DK0669912T3 (ru)
ES (1) ES2164109T3 (ru)
HK (1) HK1004985A1 (ru)
HU (1) HUT73174A (ru)
IL (3) IL126825A (ru)
PT (1) PT669912E (ru)
RU (1) RU2161155C2 (ru)
TW (1) TW401414B (ru)
WO (1) WO1995008536A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051730A1 (en) * 1993-09-22 2001-12-13 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivative and a process for the preparation thereof
KR19980703107A (ko) * 1995-03-17 1998-10-15 후지야마 아키라 N-아실피페리디닐카보닐아미노카복실산 및 당단백질 IIB/IIa 길항제와 피브리노겐-혈소판 결합 억제제로서의 이의 용도
EP0888302A1 (en) * 1996-03-13 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. N- (r)-1- 3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist
EP1184374B1 (en) * 1996-05-01 2009-01-28 Ortho-McNeil Pharmaceutical, Inc. Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
AU726594B2 (en) * 1996-05-01 2000-11-16 Ortho-Mcneil Pharmaceutical, Inc. Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
WO1999003832A1 (en) * 1997-07-14 1999-01-28 Phytera Symbion Aps Piperidine oligomers and combinatorial libraries thereof
US6066651A (en) 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
WO1999025685A1 (en) * 1997-11-18 1999-05-27 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
AU769718B2 (en) * 1998-10-12 2004-02-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing beta-alanine derivative
AUPP646598A0 (en) 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
BR0010652A (pt) * 1999-03-22 2002-07-16 Ortho Mcneil Pharm Inc Processo de preparação de ácido [s-(r*,s*)]-beta-[[[1-[1-oxo-3-(4-piperidinil)propil]-3-piperi dinil]carbonil]amino]-3-piridinapropanóico e derivados
ES2244474T3 (es) 1999-09-29 2005-12-16 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamida para el tratamiento de trastornos mediados por integrina.
AUPQ570100A0 (en) * 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
US7081460B2 (en) 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
EP1719529A4 (en) 2004-02-25 2008-05-21 Astellas Pharma Inc CONTRASTING FOR THROMBUS EDUCATION
US9345793B2 (en) 2011-08-17 2016-05-24 Piramal Imaging Sa Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi
CN105189521A (zh) 2013-02-12 2015-12-23 拜耳医药股份公司 结合至血小板特异性糖蛋白IIb/IIIa的金属螯合化合物
KR102548998B1 (ko) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03257624A (ja) * 1990-03-08 1991-11-18 Fujitsu Ltd 画面言語方式
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
CA2054627A1 (en) * 1991-02-13 1992-08-14 Yea-Shun Cheng Polypeptide skeletal muscle relaxants
WO1992019595A1 (en) * 1991-05-07 1992-11-12 Merck & Co., Inc. Fibrinogen receptor antagonists
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds

Also Published As

Publication number Publication date
DE69429328D1 (de) 2002-01-17
CA2157792C (en) 2005-05-24
PT669912E (pt) 2002-03-28
AU684547B2 (en) 1997-12-18
US6380215B1 (en) 2002-04-30
IL126825A (en) 1999-09-22
ES2164109T3 (es) 2002-02-16
DE69429328T2 (de) 2002-06-13
EP0669912A1 (en) 1995-09-06
AU7665794A (en) 1995-04-10
CA2157792A1 (en) 1995-03-30
WO1995008536A1 (en) 1995-03-30
CN1041919C (zh) 1999-02-03
HUT73174A (en) 1996-06-28
CN1116847A (zh) 1996-02-14
EP1106606A3 (en) 2003-10-22
IL126825A0 (en) 1999-08-17
HU9501845D0 (en) 1995-08-28
EP0669912B1 (en) 2001-12-05
EP1106606A2 (en) 2001-06-13
ATE210118T1 (de) 2001-12-15
DK0669912T3 (da) 2002-03-04
IL111036A0 (en) 1994-11-28
RU2161155C2 (ru) 2000-12-27
TW401414B (en) 2000-08-11
HK1004985A1 (en) 1998-12-18
IL111036A (en) 1999-07-14

Similar Documents

Publication Publication Date Title
RU95112456A (ru) Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения
CY1108367T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
DE69613365D1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
EA200400432A1 (ru) Производные мочевины
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DE69229442T2 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE69315699D1 (de) Inhibitoren gegen die aggregation von blutplättchen
RU94039545A (ru) Новые производные аденозина, способы их получения, фармацевтические композиции на их основе, способы получения фармацевтических композиций и их применение
ATE240098T1 (de) Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
EA200300900A1 (ru) Замещенные амины (варианты), способ их получения и их применение в качестве ингибиторов транспорта глицина (варианты), композиция (варианты), промежуточный иодид и способ его получения, способ лечения пациента (варианты)
RU94026088A (ru) Способ лечения шока и способ ингибирования продуцирования альфа фактора некроза опухоли
ATE288254T1 (de) Methode zur behandlung von schlaganfall
DE69622868T2 (de) Inhibitoren der blutplättchen-aggregation, die c-terminale aminosäurereste mit aminergen seitenketten enthalten
BR0214552A (pt) Composto ou um seu sal de adição de ácido farmaceuticamente aceitável, composição farmacêutica, uso do composto ou do seu sal de adição de ácido farmaceuticamente aceitável, e, método para o tratamento de uma doença
RU99108789A (ru) Ингибитор субэпителиального помутнения роговицы
TH23744A (th) สารยับยั้ง tnf - แอลฟา
BR0302183A (pt) Composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20040922